1st Circuit revives securities fraud claims against Biogen
Investors could bring a securities fraud class action alleging that statements a biotech executive made about the results of an Alzheimer's drug's clinical trials were misleading,…
Investors could bring a securities fraud class action alleging that statements a biotech executive made about the results of an Alzheimer's drug's clinical trials were misleading,…